107 related articles for article (PubMed ID: 18201769)
1. ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
Friedländer E; Barok M; Szöllosi J; Vereb G
Immunol Lett; 2008 Mar; 116(2):126-40. PubMed ID: 18201769
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
5. Anticancer antibodies.
Ross JS; Gray K; Gray GS; Worland PJ; Rolfe M
Am J Clin Pathol; 2003 Apr; 119(4):472-85. PubMed ID: 12710120
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal and bispecific antibodies as novel therapeutics.
Booy EP; Johar D; Maddika S; Pirzada H; Sahib MM; Gehrke I; Loewen S; Louis SF; Kadkhoda K; Mowat M; Los M
Arch Immunol Ther Exp (Warsz); 2006; 54(2):85-101. PubMed ID: 16648969
[TBL] [Abstract][Full Text] [Related]
7. Active and inactive conformations of the epidermal growth factor receptor.
Ferguson KM
Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003
[TBL] [Abstract][Full Text] [Related]
8. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
[TBL] [Abstract][Full Text] [Related]
9. Engineered affinity proteins for tumour-targeting applications.
Friedman M; Ståhl S
Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
[TBL] [Abstract][Full Text] [Related]
10. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
[TBL] [Abstract][Full Text] [Related]
12. Current role of antibody therapy in patients with metastatic colorectal cancer.
Pfeiffer P; Qvortrup C; Eriksen JG
Oncogene; 2007 May; 26(25):3661-78. PubMed ID: 17530020
[TBL] [Abstract][Full Text] [Related]
13. Effector mechanisms of therapeutic antibodies against ErbB receptors.
Peipp M; Dechant M; Valerius T
Curr Opin Immunol; 2008 Aug; 20(4):436-43. PubMed ID: 18585454
[TBL] [Abstract][Full Text] [Related]
14. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
15. [Antibody treatment for cancer].
Sasaki S; Ozeki I; Takekawa M; Tsujisaki M; Imai K
Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):607-11. PubMed ID: 11022675
[TBL] [Abstract][Full Text] [Related]
16. Overview of monoclonal antibodies in cancer therapy: present and promise.
Stern M; Herrmann R
Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
18. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
20. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
